Left ventricular hypertrophy reversal with labetalol and propranolol: A prospective, randomized, double-blind study
- 1 March 1990
- journal article
- conference paper
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 4 (2) , 427-433
- https://doi.org/10.1007/bf01857749
Abstract
Hypertensive patients with left ventricular hypertrophy (LVH) have increased cardiovascular morbidity and mortality. Experimental studies indicate the importance of both the alpha and beta components of the adrenergic nervous system in the development and reversal of LVH. Therefore labetalol (L), a combined alpha and beta blocker, and propranolol (P), a nonselective beta blocker, were evaluated in a randomized, double-blind study of 35 hypertensive patients with echocardiographic evidence of LVH. Following 2 weeks of placebo, L or P was titrated as needed and tolerated to maximum total daily doses of 1600 mg and 640 mg, respectively. A thiazide diuretic was added if necessary for blood pressure control. M-mode echocardiograms were performed at baseline and after 1, 3, 6 and 12 months of blood pressure control. The echocardiograms were read independently by two blinded observers for end-diastolic dimension and wall thicknesses, and left ventricular mass. Fractional shortening, cardiac output, and peripheral vascular resistance were derived using standard formulas. Both drugs reduced blood pressure significantly and comparably. Significant changes in the echocardiographic measurements were observed as early as 1 month and usually persisted throughout the study. Both drugs decreased posterior wall thickness; however, only the decrease in propranolol group achieved statistical significance. Septal wall thickness was reduced by L at 3 and 12 months. End-diastolic dimension increased significantly in the L-treated group at 3, 6, and 12 months of therapy, whereas P had no effect on this measurement. As a consequence, the calculated left ventricular mass index was reduced by P throughout the study, but remained essentially unchanged by L until the twelfth month. Neither drug adversely affected fractional shortening. Cardiac output was significantly reduced by P, but unchanged by L, despite similar effects on heart rate by both drugs. Thus, despite their similar effects on blood pressure, L and P had different effects on cardiac morphology, which may reflect varying responses to alpha-and beta-adrenergic blockade.Keywords
This publication has 30 references indexed in Scilit:
- Effect of diltiazem on left ventricular mass and diastolic filling in mild to moderate hypertensionThe American Journal of Cardiology, 1989
- Regression of left ventricular mass is accompanied by improvement in rapid left ventricular filling following antihypertensive therapy with metoprololAmerican Heart Journal, 1989
- Regression of cardiovascular structural changes by antihypertensive treatment. Functional consequences and time course of reversal as judged from clinical studies.Hypertension, 1984
- Effects of labetalol on left ventricular mass and function in hypertension — An assessment by serial echocardiographyInternational Journal of Cardiology, 1984
- Effect of acebutolol on left ventricular hemodynamics and anatomy in systemic hypertensionThe American Journal of Cardiology, 1984
- Left ventricular hypertrophy: relationship of anatomic, echocardiographic and electrocardiographic findings.Circulation, 1981
- Reproducibility of left ventricular internal dimensions with M mode echocardiography: Effects of heart size, body position and transducer angulationThe American Journal of Cardiology, 1981
- Sources of variability in echocardiographic measurementsThe American Journal of Cardiology, 1980
- Accuracy and reproducibility of new M-mode echocardiographic recommendations for measuring left ventricular dimensions.Circulation, 1980
- Norepinephrine—The myocardial hypertrophy hormone?American Heart Journal, 1976